Akrimax Pharmaceuticals, LLC
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Akrimax Pharmaceuticals, LLC
FDA Lull In Rx Promotion Citations Continues; Guidances May Be Bigger Priority
Even with recent letters, Office of Prescription Drug Promotion’s slow pace continues from 2014’s record low.
FDA Suppresses Suprenza Site, But Coupon Link Remains
FDA sends untitled letter to Citius Pharmaceuticals and licensee Akrimax for not including any risk information on webpage for weight loss product; Akrimax received a similar citation in March for a Tirosint Facebook page.
Facebook Page Cannot Leave Out Risk Information, FDA Says
Office of Prescription Drug Promotion also expresses concern that Facebook page for hypothyroidism drug Tirosint fails to include limits on the indication.
IN VIVO: Deals Shaping The Medical Industry, May 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
Company Information
- Industry
- Biotechnology
- Distributors
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice